GeneNews specializes in the commercialization of molecular diagnostics for the early detection of cancer and chronic disease. Our mission is to identify, assess and make commercially available a comprehensive menu of non-invasive risk assessment tests that provide physicians and patients with personalized clinical intelligence to improve health outcomes through the early diagnosis of disease.
GeneNews Adds Blood Test for Breast Cancer Prediction to Innovative Diagnostic Laboratory’s Offering Menu
TORONTO, CANADA (October 14, 2014): GeneNews Limited (TSX:GEN) (“GeneNews” or the “Company”) today announced that it has in-licensed two biomarker assays - sphingotest® pro-NT and sphingotest® pro-ENK – that aid physicians in identifying those females at highest risk for breast cancer in the general population. Both tests were developed by sphingotec GmbH, a Germany-based company best known for discovery and development of biomarker assays, which has recently expanded in the U.S.
GeneNews’ Innovative Diagnostic Laboratory J-V Launches Beckman Coulter’s Prostate Health Index (phi) Across U.S.
Toronto, Canada (April 24, 2014): GeneNews Limited (TSX:GEN) (“GeneNews” or the “Company”) today announced that its recently formed joint venture, Innovative Diagnostic Laboratory LLP ("IDL"), has added Beckman Coulter Diagnostics’ Prostate Health Index (phi) to its menu of advanced cancer assays and has initiated a commercial roll out of this groundbreaking test across the United States. Read the full article.
In The News
GeneNews' IDL off to flying start
BioTuesdays - GeneNews’ (TSX:GEN) recently formed U.S. joint venture, Innovative Diagnostic Laboratory (IDL), took a huge step forward in the first quarter in its goal of becoming a leader in molecular diagnostics and personalized medicine.“With a successful limited scale launch of IDL in the fourth quarter of 2013, full scale-up activities began in the first quarter of this year, with a ramp up in lab capacity, a quadrupling of the size of the sales force, incrementally higher sales of our flagship ColonSentry test, and a rollout of new tests,” GeneNews’ executive chairman, James Howard-Tripp, says in an interview with BioTuesdays.com.
A total of 14,680 diagnostic tests were processed by IDL in the latest quarter, up 346% sequentially from 3,288 tests in the 2013 fourth quarter. Of these, 12,110 were ColonSentry. In April, the lab processed 13,600 tests. Read the full article.